Effect of fenoldopam on the acute and subacute nephrotoxicity produced by amphotericin B in the dog
- PMID: 1346161
Effect of fenoldopam on the acute and subacute nephrotoxicity produced by amphotericin B in the dog
Abstract
The effect of the selective dopamine DA1 receptor agonist fenoldopam (1 microgram/kg/min i.v.) on the acute nephrotoxic response to amphotericin B (2 mg/kg i.v.) has been studied in the anesthetized dog. Animals were prepared for the measurement of blood pressure, renal blood flow, urine flow, glomerular filtration rate and sodium and potassium excretion. Amphotericin B was given over 20 min and the animals were followed for an additional 160 min. The fenoldopam infusion was started 20 min before amphotericin B and was continued for the duration of the experiment. In control animals, amphotericin B markedly increased renal vascular resistance without affecting blood pressure and thus produced a significant reduction in renal blood flow. The renal vasoconstrictor response to amphotericin B was not attenuated by fenoldopam. Concomitant with the renal vasoconstriction produced by amphotericin B was a marked reduction in glomerular filtration rate, sodium excretion and urine flow rate, which lasted for at least 160 min after amphotericin B treatment. Fenoldopam did not have any effect on the initial reductions in glomerular filtration rate, sodium excretion and urine flow rate but did produce a significant return of these parameters toward control levels by 160 min, despite the continued renal vasoconstriction. The effect of fenoldopam (0.5 microgram/kg/min) given continuously by i.v. infusion on the subacute nephrotoxic response produced by amphotericin B given every other day for 8 days was also investigated. One day after the start of the fenoldopam infusion, venous samples were drawn for the analysis of serum creatinine and blood urea nitrogen.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Intrarenally produced angiotensin II opposes the natriuretic action of the dopamine-1 receptor agonist fenoldopam in rats.J Pharmacol Exp Ther. 1991 Feb;256(2):486-91. J Pharmacol Exp Ther. 1991. PMID: 1671595
-
Attenuation of amphotericin B nephrotoxicity in the dog by the fenoldopam prodrug, SK&F R-105058.J Pharmacol Exp Ther. 1991 Jun;257(3):1243-7. J Pharmacol Exp Ther. 1991. PMID: 1675291
-
Effects of dopamine DA1-receptor blockade and angiotensin converting enzyme inhibition on the renal actions of fenoldopam in the anaesthetized dog.J Hypertens. 1991 Dec;9(12):1143-50. J Hypertens. 1991. PMID: 1685741
-
Clinical experience with intravenous fenoldopam.Am J Hypertens. 1990 Jun;3(6 Pt 2):120S-125S. doi: 10.1093/ajh/3.6.120s. Am J Hypertens. 1990. PMID: 1974440 Review.
-
The pharmacology of fenoldopam.Am J Hypertens. 1990 Jun;3(6 Pt 2):116S-119S. doi: 10.1093/ajh/3.6.116s. Am J Hypertens. 1990. PMID: 1974439 Review.
Cited by
-
Role of diuretics and lipid formulations in the prevention of amphotericin B-induced nephrotoxicity.Eur J Clin Pharmacol. 2013 Jul;69(7):1351-68. doi: 10.1007/s00228-013-1472-1. Epub 2013 Jan 30. Eur J Clin Pharmacol. 2013. PMID: 23361383 Review.
-
Evaluation of hypokalemia and potassium supplementation during administration of liposomal-amphotericin B.Exp Ther Med. 2014 Apr;7(4):941-946. doi: 10.3892/etm.2014.1534. Epub 2014 Feb 11. Exp Ther Med. 2014. PMID: 24669255 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical